logo-loader
RNS
BioPharma Credit PLC

BioPharma Credit PLC - NEW INVESTMENT

RNS Number : 5508H
BioPharma Credit PLC
09 June 2026
 

9 June 2026

  

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

NEW INVESTMENT OF UP TO CHF75 MILLION IN IDORSIA PHARMACEUTICALS

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment trust, is pleased to announce that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP ("BioPharma-V"), have entered into a new senior secured loan agreement (the "Loan Agreement") with Idorsia Pharmaceuticals Ltd ("Idorsia").  The Company will invest up to CHF 75 million and BioPharma-V will invest up to an additional CHF 175 million in parallel, with the Company acting as collateral agent.

 

Under the Loan Agreement, the Company will invest up to CHF 75 million across three tranches, subject to customary conditions precedent:

·    Tranche A of CHF 45 million will be funded 10 business days after the signing of the Loan Agreement;

·    Tranche B of CHF 15 million (or its USD equivalent) is available to be drawn until 31 December 2026; and

·    Tranche C of CHF 15 million (or its USD equivalent) is available to be drawn until 30 June 2027, subject to achievement of certain net sales milestones.

The loan will mature in June 2031 and any CHF loan will bear interest at a fixed 7.00 per cent. per annum.  Any USD loans will bear interest at 3-month SOFR plus 5.75 per cent. per annum subject to a 3.25 per cent. SOFR floor. An additional one-time consideration of 1.50 per cent. of each tranche is payable by Idorsia upon the funding of each respective tranche. Certain other prepayment and makewhole fees, as well as exit consideration, are also payable by Idorsia in connection with repayment of the loans. The Company and BioPharma-V will use forward contracts to hedge the CHF exposure. The forward hedge is expected to generate a positive carry, resulting in expected USD-denominated returns for this investment that are broadly in line with those of other investments in the portfolio.

Idorsia is a Switzerland-based biopharmaceutical company specialized in the discovery, development, and commercialization of innovative small molecules with a market capitalisation of ~CHF 1.09 billion (Ticker: IDIA - SWX). Idorsia's lead product is Quviviq (daridorexant), a dual orexin receptor antagonist (DORA) which blocks the binding of wake-promoting orexin neuropeptides. Rather than inducing sleep through broad inhibition of brain activity, daridorexant selectively blocks the activation of orexin receptors. Consequently, daridorexant decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages. In 2025, Idorsia's reported total revenue was CHF 221m of which CHF 142m were Quviviq product sales. In the first quarter of 2026, Idorsia reported Quviviq product sales of CHF 44m (up 74 per cent. from the same period in 2025). 

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFEERIIAIIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read